RankAlpha logo
Back to Rankings

CDIO

Cardio DiagnosticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
View Chart
Current thesis
The best bull argument is that company sources now show more tangible operating infrastructure than before: a launched internal CLIA lab, stated COGS reduction, ongoing reimbursement work, and partner-led expansion into India could improve unit economics if test adoption starts to scale [#8-K-2026-02-19] [#10-K-2026-03-13].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
ATM issuance has already been used heavily, so further equity dilution remains a live risk.
Momentum
100
Value
58
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $2.40 · Bear $1.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-12 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $2.00
Why
Momentum100 · Δ7d -
Value58 · Δ7d -0.3
Sentiment47 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.4
Sentiment
47
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 99.9 / Value 58.2 / Sentiment 47.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$5.09M
Beta
2.89
Shares Out
2.96M
P/E (TTM) · Derived
-0.5
P/S (TTM)
344.63
P/FCF (TTM) · Derived
-0.56
Rev YoY
+185.1%
EPS YoY
-35.1%
Gross Margin
-2512.9%
Op Margin
-41401.1%
Net Debt
-$4.42M
Current Ratio
15.76
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology